Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05387460
Other study ID # 2022-TJ-R-RBM
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date October 1, 2021
Est. completion date July 1, 2023

Study information

Verified date May 2022
Source Tongji Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Retrospectively collect preoperative transvaginal B-mode ultrasound (BMUS), color Doppler flow imaging (CDFI) and three-dimensional ultrasound (3D-US) images and clinical data in patients with non-endometrial cancer diseases and endometrial cancer confirmed by pathology. They were grouped as training set(Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology) and external validation set(Women's Hospital, School of Medicine, Zhejiang University) . Radiomics features were extracted from corresponding transvaginal ultrasound images. Then, the minimum redundancy maximum relevance (mRMR) algorithm and the least absolute shrinkage and selection operator (LASSO) regression were used to select the non- malignant or malignant status-related features and cervical stromal invasion (CSI) status or non-CSI status features and construct the transvaginal ultrasound radiomics score (Rad-score). Multivariate logistic regression was performed using the three radiomics score together with clinical data, and subsequently develop a nomogram to diagnosis endometrial cancer and CSI respectively. The performance of the nomogram was assessed by discrimination, calibration, and clinical usefulness in the training and external validation set.


Description:

Endometrial Cancer is the second most common gynecological cancer in China and the first in Western countries. The common clinical symptom of endometrial cancer is vaginal bleeding, which occurs in about 10% of postmenopausal women. Most patients with postmenopausal vaginal bleeding are diagnosed with benign diseases, and less than 10% of patients are diagnosed with endometrial cancer. Early diagnosis is crucial for the prognosis of patients with endometrial cancer. The 5-year survival rate of patients with endometrial cancer which lesions localized to the uterus is about 95%, while the survival rate of patients with regional and distant metastasis is reduced to less than 70% and 20%. Surgery is the main treatment of endometrial cancer. CSI is one of the main criteria for determining the follow-up treatment. According to NCCN guidelines, Total Hysterectomy and Bilateral Salpingo-Oophorectomy (THBSO) are standard treatments for patients with endometrioid carcinoma without CSI. While extensive hysterectomy or surgery after radiotherapy is appropriate for patients with CSI. Therefore, accurate assessment of CSI status in patients with EC before operation is important for the formulation of accurate surgical strategies. Endometrial biopsy has been considered the gold standard for assessing endometrial cancer. However, it is limited because of increased cost, sample errors, related complications such as pain, bleeding, inability to evaluate the extent of tumor invasion and easy to cause tumor spread. CT/MR are alternative ways with high cost and complications. Transvaginal ultrasound examination is considered as the first imaging investigation for endometrial cancer. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma indicate that transvaginal ultrasound can be used instead of magnetic resonance imaging to detect cervical stromal infiltration under the operation of experienced doctors. Improving the performance of ultrasonic diagnosis is significant for how to choose the follow-up treatment and reduce the cost and risk of overtreatment. Radiomics refers to high-throughput mining of quantitative image features from medical imaging. Radiomics derived data, when combined with other pertinent clinicopathological features, can produce accurate and robust evidence-based decision-making systems. Multimodal radiomics can provide more imaging feature information than single modal radiomics, which showed better diagnostic performance in previous study of kinds of cancer diseases.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 2000
Est. completion date July 1, 2023
Est. primary completion date December 1, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients diagnosed by operation and pathology 2. Patients with preoperative transvaginal ultrasound images Exclusion Criteria: 1. Past history of gynecological malignant tumors 2. Previous pelvic surgery or radiotherapy or chemotherapy 3. Poor image quality 4. Incomplete pathological or diagnosis report

Study Design


Intervention

Diagnostic Test:
radiomics
Radiomics refers to high-throughput mining of quantitative image features from medical imaging. Radiomics derived data, when combined with other pertinent clinicopathological features, can produce accurate and robust evidence-based decision-making systems. Multimodal radiomics can provide more imaging feature information than single modal radiomics, which showed better diagnostic performance in previous study of kinds of cancer diseases.

Locations

Country Name City State
China Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei

Sponsors (2)

Lead Sponsor Collaborator
Tongji Hospital Women's Hospital School Of Medicine Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUC value Area under the receiver operating characteristic (ROC) curve (AUC) through study completion, an average of 1 year
Secondary Diagnostic specificity diagnosis specificity of intelligent ultrasound analysis through study completion, an average of 1 year
Secondary Diagnostic sensitivity diagnosis sensitivity of intelligent ultrasound analysis through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05796518 - Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors N/A
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06463028 - Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Completed NCT03820024 - MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback N/A
Active, not recruiting NCT05082025 - Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Phase 2
Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer
Completed NCT05378152 - Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity N/A
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Recruiting NCT04569773 - Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Not yet recruiting NCT05998798 - Revealing Engagement Patterns Among Endometrial Cancer Patients
Not yet recruiting NCT06073184 - Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium Phase 2
Not yet recruiting NCT06366347 - ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab Phase 2
Terminated NCT02907073 - Positron Emission Tomography (PET) Imaging Studies With NIS Reporter Phase 1/Phase 2
Completed NCT02413606 - ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More? N/A